DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing
1 Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc., Seattle, Washington 98109, USA
2 Institute for Translational Oncology and Immunology (TrOn), Mainz, Germany
3 NuGEN Technologies, Inc., Seattle, Washington, USA
4 University of Washington, Seattle, Washington, USA
5 Pfizer, Inc., San Diego, California, USA
6 Merck Research Laboratories, Boston, Massachusetts, USA
7 Amgen, Inc., Seattle, Washington, USA
BMC Genomics 2010, 11:244 doi:10.1186/1471-2164-11-244Published: 16 April 2010
DNA copy number variations occur within populations and aberrations can cause disease. We sought to develop an improved lab-automatable, cost-efficient, accurate platform to profile DNA copy number.
We developed a sequencing-based assay of nuclear, mitochondrial, and telomeric DNA copy number that draws on the unbiased nature of next-generation sequencing and incorporates techniques developed for RNA expression profiling. To demonstrate this platform, we assayed UMC-11 cells using 5 million 33 nt reads and found tremendous copy number variation, including regions of single and homogeneous deletions and amplifications to 29 copies; 5 times more mitochondria and 4 times less telomeric sequence than a pool of non-diseased, blood-derived DNA; and that UMC-11 was derived from a male individual.
The described assay outputs absolute copy number, outputs an error estimate (p-value), and is more accurate than array-based platforms at high copy number. The platform enables profiling of mitochondrial levels and telomeric length. The assay is lab-automatable and has a genomic resolution and cost that are tunable based on the number of sequence reads.